Tags

Type your tag names separated by a space and hit enter

Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis.
BMJ Open. 2015 Apr 02; 5(4):e007766.BO

Abstract

OBJECTIVES

To investigate the differences of clinical features, cerebrospinal fluid (CSF), MRI findings and response to steroid therapies between patients with optic neuritis (ON) who have myelin oligodendrocyte glycoprotein (MOG) antibodies and those who have seronegative ON.

SETTING

We recruited participants in the department of neurology and ophthalmology in our hospital in Japan.

METHODS

We retrospectively evaluated the clinical features and response to steroid therapies of patients with ON. Sera from patients were tested for antibodies to MOG and aquaporin-4 (AQP4) with a cell-based assay.

PARTICIPANTS

Between April 2009 and March 2014, we enrolled serial 57 patients with ON (27 males, 30 females; age range 16-84 years) who ophthalmologists had diagnosed as having or suspected to have ON with acute visual impairment and declined critical flicker frequency, abnormal findings of brain MRI, optical coherence tomography and fluorescein fundus angiography at their onset or recurrence. We excluded those patients who fulfilled the diagnostic criteria of neuromyelitis optica (NMO)/NMO spectrum disorders (NMOSD), MS McDonald's criteria, and so on. Finally we defined 29 patients with idiopathic ON (14 males, 15 females, age range 16-84 years).

RESULTS

27.6% (8/29) were positive for MOG antibodies and 3.4% (1/29) were positive for AQP4. Among the eight patients with MOG antibodies, five had optic pain (p=0.001) and three had prodromal infection (p=0.179). Three of the eight MOG-positive patients showed significantly high CSF levels of myelin basic protein (p=0.021) and none were positive for oligoclonal band in CSF. On MRIs, seven MOG-positive patients showed high signal intensity on optic nerve, three had a cerebral lesion and one had a spinal cord lesion. Seven of the eight MOG-positive patients had a good response to steroid therapy.

CONCLUSIONS

Although not proving primary pathogenicity of anti-MOG antibodies, the present results indicate that the measurement of MOG antibodies is useful in diagnosing and treating ON.

Authors+Show Affiliations

Unit of Translational Medicine, Department of Neurology and Strokology, Nagasaki University Hospital, Nagasaki, Japan.Unit of Translational Medicine, Department of Neurology and Strokology, Nagasaki University Hospital, Nagasaki, Japan Faculty of Engineering Department of Engineering, Medical Engineering Course, Nagasaki Institute of Applied Science, Nagasaki, Japan.Department of Neurology, Kanazawa Medical University, Ishikawa, Japan.Department of Ophthalmology, Nagasaki University Hospital, Nagasaki, Japan.Unit of Translational Medicine, Department of Neurology and Strokology, Nagasaki University Hospital, Nagasaki, Japan.Unit of Translational Medicine, Department of Neurology and Strokology, Nagasaki University Hospital, Nagasaki, Japan.Unit of Translational Medicine, Department of Neurology and Strokology, Nagasaki University Hospital, Nagasaki, Japan.Unit of Translational Medicine, Department of Neurology and Strokology, Nagasaki University Hospital, Nagasaki, Japan.Unit of Translational Medicine, Department of Neurology and Strokology, Nagasaki University Hospital, Nagasaki, Japan.Unit of Translational Medicine, Department of Neurology and Strokology, Nagasaki University Hospital, Nagasaki, Japan.Unit of Translational Medicine, Department of Neurology and Strokology, Nagasaki University Hospital, Nagasaki, Japan.Unit of Translational Medicine, Department of Neurology and Strokology, Nagasaki University Hospital, Nagasaki, Japan.Unit of Translational Medicine, Department of Neurology and Strokology, Nagasaki University Hospital, Nagasaki, Japan.

Pub Type(s)

Evaluation Study
Journal Article

Language

eng

PubMed ID

25838512

Citation

Nakajima, Hideki, et al. "Antibodies to Myelin Oligodendrocyte Glycoprotein in Idiopathic Optic Neuritis." BMJ Open, vol. 5, no. 4, 2015, pp. e007766.
Nakajima H, Motomura M, Tanaka K, et al. Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis. BMJ Open. 2015;5(4):e007766.
Nakajima, H., Motomura, M., Tanaka, K., Fujikawa, A., Nakata, R., Maeda, Y., Shima, T., Mukaino, A., Yoshimura, S., Miyazaki, T., Shiraishi, H., Kawakami, A., & Tsujino, A. (2015). Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis. BMJ Open, 5(4), e007766. https://doi.org/10.1136/bmjopen-2015-007766
Nakajima H, et al. Antibodies to Myelin Oligodendrocyte Glycoprotein in Idiopathic Optic Neuritis. BMJ Open. 2015 Apr 2;5(4):e007766. PubMed PMID: 25838512.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis. AU - Nakajima,Hideki, AU - Motomura,Masakatsu, AU - Tanaka,Keiko, AU - Fujikawa,Azusa, AU - Nakata,Ruka, AU - Maeda,Yasuhiro, AU - Shima,Tomoaki, AU - Mukaino,Akihiro, AU - Yoshimura,Shunsuke, AU - Miyazaki,Teiichiro, AU - Shiraishi,Hirokazu, AU - Kawakami,Atsushi, AU - Tsujino,Akira, Y1 - 2015/04/02/ PY - 2015/4/4/entrez PY - 2015/4/4/pubmed PY - 2016/1/6/medline SP - e007766 EP - e007766 JF - BMJ open JO - BMJ Open VL - 5 IS - 4 N2 - OBJECTIVES: To investigate the differences of clinical features, cerebrospinal fluid (CSF), MRI findings and response to steroid therapies between patients with optic neuritis (ON) who have myelin oligodendrocyte glycoprotein (MOG) antibodies and those who have seronegative ON. SETTING: We recruited participants in the department of neurology and ophthalmology in our hospital in Japan. METHODS: We retrospectively evaluated the clinical features and response to steroid therapies of patients with ON. Sera from patients were tested for antibodies to MOG and aquaporin-4 (AQP4) with a cell-based assay. PARTICIPANTS: Between April 2009 and March 2014, we enrolled serial 57 patients with ON (27 males, 30 females; age range 16-84 years) who ophthalmologists had diagnosed as having or suspected to have ON with acute visual impairment and declined critical flicker frequency, abnormal findings of brain MRI, optical coherence tomography and fluorescein fundus angiography at their onset or recurrence. We excluded those patients who fulfilled the diagnostic criteria of neuromyelitis optica (NMO)/NMO spectrum disorders (NMOSD), MS McDonald's criteria, and so on. Finally we defined 29 patients with idiopathic ON (14 males, 15 females, age range 16-84 years). RESULTS: 27.6% (8/29) were positive for MOG antibodies and 3.4% (1/29) were positive for AQP4. Among the eight patients with MOG antibodies, five had optic pain (p=0.001) and three had prodromal infection (p=0.179). Three of the eight MOG-positive patients showed significantly high CSF levels of myelin basic protein (p=0.021) and none were positive for oligoclonal band in CSF. On MRIs, seven MOG-positive patients showed high signal intensity on optic nerve, three had a cerebral lesion and one had a spinal cord lesion. Seven of the eight MOG-positive patients had a good response to steroid therapy. CONCLUSIONS: Although not proving primary pathogenicity of anti-MOG antibodies, the present results indicate that the measurement of MOG antibodies is useful in diagnosing and treating ON. SN - 2044-6055 UR - https://www.unboundmedicine.com/medline/citation/25838512/Antibodies_to_myelin_oligodendrocyte_glycoprotein_in_idiopathic_optic_neuritis_ L2 - https://bmjopen.bmj.com/lookup/pmidlookup?view=long&pmid=25838512 DB - PRIME DP - Unbound Medicine ER -